23:20 , May 25, 2018 |  BC Extra  |  Politics & Policy

China rare disease list could promote R&D, regulatory filings

Five Chinese government agencies, including the State Drug Administration and the National Health Commission, published a national list of 121 qualified rare diseases to support diagnosis and treatment of such conditions in a move that...
02:06 , May 11, 2018 |  BC Innovations  |  Finance

Amplifying oligos

The last five years have seen a steady stream of preclinical deals for antisense, siRNA and mRNA therapies that suggests pharmas are taking the modalities seriously as alternatives to traditional small molecules and antibodies. But...
00:46 , Apr 28, 2018 |  BioCentury  |  Strategy

The outsiders

As he retires from Sanofi, Elias Zerhouni has advice for the biopharma industry: the traditional executive mold must be expanded. On April 24, Sanofi announced Zerhouni would retire on June 30 and that John Reed, former...
19:09 , Apr 20, 2018 |  BC Week In Review  |  Company News

Target ALS and partners launch biomarker study

Target ALS Foundation (New York, N.Y.) is partnering with the Muscular Dystrophy Association (MDA) (Chicago, Ill.), the CReATe Consortium and 10 industry partners to conduct a study to validate biomarker candidates for amyotrophic lateral sclerosis. The...
20:26 , Apr 19, 2018 |  BC Extra  |  Company News

Target ALS, partners launch biomarker study

Target ALS Foundation is partnering with the Muscular Dystrophy Association (MDA), the CReATe Consortium and 10 industry partners to conduct a study to validate biomarker candidates for amyotrophic lateral sclerosis. The study will seek to...
22:51 , Apr 6, 2018 |  BioCentury  |  Finance

Picking season

  Macroeconomic risks, surging volatility and a tail-off in the M&A market since January have done little to change the buyside’s strategy of overweighting small- and mid-cap biotechs. In fact, the 12 investors who spoke to BioCentury...
18:09 , Mar 16, 2018 |  BC Week In Review  |  Company News

Sanofi declines option for Alnylam's lumasiran

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) declined to exercise its exclusive option to obtain development and commercialization rights to lumasiran (ALN-GO1) outside the U.S., Canada and Western Europe....
21:11 , Mar 12, 2018 |  BC Extra  |  Company News

Sanofi declines option for Alnylam's lumasiran

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) declined to exercise its exclusive option to obtain development and commercialization rights to lumasiran (ALN-GO1) outside the U.S., Canada and Western Europe....
22:39 , Feb 28, 2018 |  BC Extra  |  Company News

Termeer celebrated on Rare Disease Day

Biotech pioneer Henri Termeer, who passed away in 2017, was honored Wednesday at a ceremony in Cambridge, Mass. The North Plaza at Cambridge’s Kendall Square was renamed Henri A. Termeer Square. The Henri A. Termeer...
18:48 , Feb 8, 2018 |  BC Extra  |  Company News

Management tracks: CRISPR, Arcturus

Gene editing company CRISPR Therapeutics AG (NASDAQ:CRSP) said CSO Bill Lundberg is stepping down. He will become head of CRISPR's scientific advisory board. RNA therapeutics company Arcturus Therapeutics Ltd. (NASDAQ:ARCT) said President and CEO Joseph Payne...